Samsung Biologics' All-Cash Tender Offer to Acquire PolyPeptide Group AG for CHF 44.31 per Share (CHF 1.46 Billion / $1.8 Billion, Representing a 40% Premium to the Undisturbed Share Price) Continues to Progress With the Formal Tender Offer Prospectus Expected to Be Published by End of August 2026 and Shareholder Acceptance From PolyPeptide's Largest Individual Shareholder Draupnir Holding B.V. (Approximately 55.65% Stake) Already Committed to Tender; The Transaction Would Substantially Expand Samsung Biologics' Peptide CDMO Manufacturing Footprint Beyond Its Existing Antibody and Antibody-Drug Conjugate Focus and Position the Combined Entity to Address the Rapidly Growing Peptide Therapeutics Demand Particularly in Obesity and Diabetes (GLP-1 Therapies); Closing Expected Towards the End of 2026 Subject to Minimum Acceptance Threshold of 66⅔% and Applicable Regulatory Approvals
Samsung Biologics' all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share (CHF 1.46 billion / $1.8 billion, representing a 40% premium to the undisturbed share price of CHF 31.65) continues to progress. The formal tender offer prospectus is expected to be published by end of August 2026 and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange following a ten trading-day cooling-off period under Swiss takeover law. PolyPeptide's largest individual shareholder Draupnir Holding B.V. (owning approximately 55.65% of shares outstanding) has committed to tender all of its shares into the offer. PolyPeptide's independent Board of Directors unanimously recommends that shareholders accept Samsung Biologics' offer. The transaction would substantially expand Samsung Biologics' peptide CDMO manufacturing footprint beyond its existing antibody and antibody-drug conjugate focus, positioning the combined entity to address the rapidly growing peptide therapeutics demand particularly in obesity and diabetes GLP-1 therapies (Novo Nordisk Wegovy and Ozempic, Eli Lilly Zepbound and Mounjaro), amylin analogs (cagrilintide), and next-generation combination peptide drugs. PolyPeptide operates commercial-scale peptide API manufacturing across the US, Europe, and India. Closing is expected towards the end of 2026 subject to a minimum acceptance threshold of 66⅔% and applicable regulatory approvals.